Ucb SA

BE

UCB

Health Care

64.93 ₽

Current price

Strong sell
64.93 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    1148 / 1328

  • Position in country

    158 / 173

  • Return on Assets, %

    2.1

    -2.7

  • Net income margin, %

    1.2

    2.8

  • EBITDA margin, %

    20.5

    10.8

  • Debt to Equity, %

    33.8

    19.2

  • Intangible assets and goodwill, %

    61

    3.6

  • Revenue CAGR 3Y, %

    -0.6

    8.5

  • Revenue Y, % chg

    -1.4

    0.5

  • P/E

    68.5

    22.7

  • P/BV

    2.5

    1.5

  • P/S

    4.4

    2.3

  • EV/S

    4.8

    2.4

  • EV/EBITDA

    21.1

    7.4

  • Average Analyst recommendation

    Hold

    Hold

  • Average upside forecasts, %

    8

    51.3

  • Forward P/E

    24.5

    15.6

  • Dividend Yield, %

    1.1

    1.7

  • Forward Dividend Yield, %

    1.1

    0.2

  • Expected dividend per share

    0.7

    0

  • Payout Ratio, %

    73.5

    30.3

  • Dividend Ex Date

    2023-05-01

Get an analytical review of this company

Competitors

Ranks

  • Novo Nordisk A/S

    00%

  • AstraZeneca PLC

    00%

  • Eli Lilly and Co

    00%

  • Roche Holding AG

    00%

  • Novartis AG

    00%

  • Financiere de Tubize SA

    00%

  • Johnson & Johnson

    00%

  • Merck & Co Inc

    00%

  • Ucb SA

    00%

  • Pfizer Inc

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    Belgium

  • Sector

    Health Care

  • Industry group

    Pharmaceuticals, Biotechnology & Life Sciences

  • Industry

    Pharmaceuticals

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    25166

  • Ticker

    UCBJY.PK

  • ISIN

    US9034801012

  • IPO date

    1987-01-02

  • Availability on Russian exchanges

    No

  • Reporting for

    2024-02-28

  • Date fact. publication of reports

    2023-12-31

Company Description

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.